TNDM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tandem Diabetes Care Inc (TNDM) is not an immediate buy for a beginner investor with a long-term perspective. The technical indicators are bearish, and while there are some positive catalysts, the lack of strong financial data and mixed analyst ratings suggest waiting for clearer signals before investing.
The technical indicators are bearish. The MACD is negatively expanding, the RSI is neutral at 30.826, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level at 15.39, with resistance levels at 17.507 and 19.623.
Wells Fargo upgraded the stock to Overweight with a price target of $27, citing the company's pharmacy model as transformational and de-risking faster than expected. Hedge funds are significantly increasing their positions, with an 870.81% increase in buying over the last quarter.
Multiple analysts, including Citi, Goldman Sachs, and BofA, have lowered their price targets recently, citing challenges in the MedTech sector and concerns about the company's ambitious strategy. Technical indicators are bearish, and there is no recent news or congress trading data to provide additional support.
No financial data available for analysis.
Analyst ratings are mixed. While Wells Fargo and Rothschild & Co Redburn are optimistic, other firms like Citi, Goldman Sachs, and BofA have lowered their price targets, reflecting cautious sentiment.
